OrthoPediatrics (KIDS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

OrthoPediatrics

NasdaqGM•Healthcare•Medical Devices

$31.43-0.10(<0.01%)Market open

Market Cap

$734.99M

P/S

2.8x

P/B

2.2x

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

How this company scores

WeakMetricSide Score: 54/100

Grade capped at D — Interest coverage below 1× (-2.4x) — earnings cannot cover interest. Strongest: Growth (21/25); weakest: Profitability (10/25).

Profitability10/25

Growth21/25

Balance Sheet & Red Flags12/25

Cash & Earnings Quality11/25

Strengths

Growing revenueLow leverageProfit converts from growthConsistent growth

Grade capped at D

Interest coverage below 1× (-2.4x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 984.3x5y range 109.0x – 984.3x

Currently above its 4-quarter median.

P/S · 2.8x5y range 1.5x – 11.9x

Currently below its 20-quarter median.

P/B · 2.2x5y range 1.1x – 5.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $734.99M

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $264.14M
Q. Revenue: $72.66M
TTM EBITDA: $-2.15M
TTM Op. Income: $-24.80M
Q. Op. Income: $-4.22M
TTM Net Income: $-33.88M
Q. Net Income: $-5.93M
EPS: $-0.25
Shares Out.: $24.15M

$264.14M in TTM revenue grew 16.1% YoY, reaching $72.66M last quarter. TTM EBITDA of $-2.15M and TTM operating income of $-24.80M show growth is flowing through to the bottom line. However, net income is negative at $33.88M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 74.3%
EBITDA Margin: 1.9%
Op. Margin: -5.8%
Net Margin: -8.2%

Op. margin of -5.8% is up 9.6% YoY — cost efficiency is improving. Net margin at -8.2% and gross margin of 74.3% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 62% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.8x
P/B Ratio: 2.2x

P/S of 2.8x and P/B of 2.2x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $509.09M
Cash: $17.14M
Long-Term Debt: $98.19M
Book Value: $339.35M
D/E Ratio: 0.3
Debt/EBITDA: 70.3

With $509.09M in assets and $98.19M in long-term debt, D/E is 0.3and book value is $339.35M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $4.51M
TTM Free Cash Flow: $3.18M
FCF Margin: 1.2%
FCF / Net Income: -0.1

TTM FCF of $3.18M on $4.51M in operating cash flow. The FCF / Net Income ratio of -0.1x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.